PRLD stock icon

Prelude Therapeutics
PRLD

$3.82
3.1%
 

About: Prelude Therapeutics Incorp is a clinical-stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.

Employees: 128

0
Funds holding %
of 6,702 funds
Analysts bullish %
News positive %

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

40% more first-time investments, than exits

New positions opened: 7 | Existing positions closed: 5

9% more capital invested

Capital invested by funds: $148M [Q4 2023] → $162M (+$13.9M) [Q1 2024]

4% more funds holding

Funds holding: 56 [Q4 2023] → 58 (+2) [Q1 2024]

1.04% less ownership

Funds ownership: 63.33% [Q4 2023] → 62.29% (-1.04%) [Q1 2024]

27% less repeat investments, than reductions

Existing positions increased: 16 | Existing positions reduced: 22

Research analyst outlook

2 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target
$5
31%
upside
Avg. target
$6
57%
upside
High target
$7
83%
upside

2 analyst ratings

positive
50%
neutral
50%
negative
0%
JMP Securities
Reni Benjamin
83%upside
$7
Market Outperform
Initiated
13 Mar 2024
HC Wainwright & Co.
Robert Burns
31%upside
$5
Neutral
Downgraded
20 Feb 2024

Financial journalist opinion